Related Experiment Videos

No association between oxidative stress and IL-6 in NIDDM patients with nephropathy

S Alsancak1, M Aydin, A Yildiz

  • 1Department of Biochemistry, Istanbul Faculty of Medicine, Istanbul University, Capa, Istanbul, Turkey.

Folia Biologica
|January 30, 2004
PubMed

Insights

Oxidative stress, indicated by malondialdehyde (MDA) levels, is elevated in diabetes with nephropathy. Interleukin-6 (IL-6) levels were not significantly different between diabetic patient groups, suggesting it may not be a useful marker for diabetic nephropathy.

Area of Science:

  • Endocrinology and Metabolism
  • Nephrology
  • Biochemistry

Background:

  • Oxidative stress is implicated in the pathogenesis of diabetes and its complications, including nephropathy.
  • Cytokine overproduction has been proposed as a contributor to metabolic abnormalities in diabetes.

Purpose of the Study:

  • To investigate the role of oxidative stress and inflammation in non-insulin-dependent diabetes mellitus (NIDDM) with varying stages of nephropathy.
  • To measure plasma malondialdehyde (MDA) as a marker of oxidative stress and interleukin-6 (IL-6) levels in diabetic patients.

Main Methods:

  • Plasma MDA and IL-6 levels were measured in three groups: healthy controls, NIDDM patients without nephropathy, and NIDDM patients with advanced nephropathy.
  • Statistical analysis was performed to compare marker levels across the groups.

Main Results:

  • Plasma MDA levels were significantly higher in NIDDM patients with advanced nephropathy compared to those without nephropathy.
  • MDA levels were also significantly higher in NIDDM patients without nephropathy compared to the control group.
  • While IL-6 levels were elevated in diabetic groups compared to controls, no significant differences were observed between the diabetic patient groups.

Conclusions:

  • Oxidative stress, as indicated by elevated MDA, appears to play a significant role in the development and progression of diabetic nephropathy.
  • Interleukin-6 (IL-6) may not be a reliable biomarker for evaluating the presence or severity of diabetic nephropathy.

Related Concept Videos